Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Background The efficacy and safety of risankizumab as compared with ustekinumab in
patients with Crohn's disease are unknown. Methods In this phase 3b, multicenter, open …

Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …

Psoriasis is caused by a complex interplay between the immune system, psoriasis-
associated susceptibility loci, autoantigens, and multiple environmental factors. Over the last …

Background Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating
moderate to severe psoriasis in a phase II trial. Objectives We sought to compare efficacy …

Background Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal
antibody, was efficacious in psoriasis. Objective We sought to assess efficacy and safety of …

Background Psoriasis is an autoimmune disease that affects approximately 100 million
people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We …

For the past three decades, the use of genomics to inform drug discovery and development
pipelines has generated both excitement and scepticism. Although earlier efforts …